Pfizer (PFE) announced the completion of its acquisition of Seagen (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43B. As previously disclosed, to address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio in the U.S. to the American Association for Cancer Research, or AACR.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer’s (NYSE:PFE) Disappointing FY24 Guidance Rattles Investors
- Unusual call flow in option market yesterday
- Pfizer falls about 7% to $26.69 after providing FY24 guidance
- Pfizer says FY24 guidance includes Seagen acquisition
- Pfizer sees annual net cost savings of ‘at least’ $4B
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue